OrbiMed

Venture Capital

Profile

Headquarters
New York, New York, United States
Investments
1
Companies
1

Capital

Total Deployed
$370M
Lead Rounds
0

Portfolio

1 company
Candid Therapeutics $875M
Private San Diego, California, United States

Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb.

Investment data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.